Alimta

... Taiwan News Online GO Home Search Politics Travel High Tech Business Culture Education E-Learning Society Community Sports Peoples Life & Leisure World ¥xÆW·s»D Editorial Government must manage interaction with PRC The recent statement by a spokesman for the Taiwan Affairs Office of the People's Republic....

[Full story] Opinion Gaza retreat may be setback for peace When U.S.

President George W.

Bush stood alongside Israeli Prime Minister Ariel Sharon at...

[Full story] Perspective Bitter rivalries may impede U.N.

reforms Since the United Nations was born in the aftermath of World War II, powerful...

[Full story] Forum Youth Advisory Committee and NGO symposium Forum, prepared by the newspaper's Editorial Department...

[Full story] Kabayan Pope's legacy lives on in people's minds Catholics all over the world cherish an encounter with the Papal Pontiff in their lifetime...

[Full story] World Drug pullout casts doubt on industry's future 2005-04-15 / Associated Press / U.S.

drug makers are expected to report a lackluster first quarter, reflecting an ongoing struggle with product withdrawals, a dearth of new drugs in the pipeline and increased competition from generics.

Profits at most major drug makers will be driven by the companies' ability to hold down costs, rather than by bringing in more revenue from existing products, said C.J.

Sylvester, an analyst with Banc of America...

... Research and Markets: Combined Sales for the Top Three Breast Cancer Hormone Therapies on the Market Reaching More Than $1.8 Billion Research and Markets: Combined Sales for the Top Three Breast Cancer Hormone Therapies on the Market Reaching More Than $1.8 Billion Research and Markets logo.

(PRNewsFoto) LONDON XEN 08/20/2004 DUBLIN, Ireland, April 14 /PRNewswire/ - Research and Markets (http://www.researchandmarkets.com/reports/c15791 ) has announced the addition of Analytical Tool - Breast Cancer R&D Comprehensive Guide to their offering.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH ) Production of an analytical tool to analyze the future competitive situation of breast cancer therapeutics.

More updated and extensive, this version pays considerable attention both to the hormone-based therapeutics as well as the new drugs under development.

As new data is emerging, for the recent approved aromatase inhibitor, the therapeutic options are about to change.

Replacing Tamoxifen, a selective estrogen receptor modulator that has been used for more than 20 years to treat patients with advanced breast cancer.

Important aspects, that in turn changes the situation for all investigational drugs, which have to climb over this new barrier to gain regulatory approval.

A proof that breast cancer market produces lucrative returns is the near to 50% increase of sales between the year 2003 and 2004 for most of the aromatase inhibitors.

Overall...

... The Daily Telegraph | Chemo drug too expensive for PBS, says committee NEWS Home Breaking News Top Stories Sport Confidential Business Small Business Entertainment World Opinion Horoscopes Here's Luck Photo Galleries FEEDBACK Send Feedback Read Feedback Letter to the editor CLASSIFIEDS CareerOne Real Estate Cars Guide Sell Your Car Place an Ad More Classifieds Travel homesite TRIVIA On This Day Today's Birthdays Trivia Quiz SERVICES Archives Buy a photo Home Delivery About Us Contact Us SurfWatch Sponsorship OUR LIFTOUTS Sydney Live Sports Stars Connect Home Top Stories Story 4.51pm Chemo drug too expensive for PBS, says committee April 14, 2005 A chemotherapy drug that can prolong survival for mesothelioma victims was too expensive to be listed under the Pharmaceutical Benefits Scheme, the Pharmaceutical Benefits Advisory Committee (PBAC) said today.

Committee chairman Professor Lloyd Sansom said the drug, "This particular drug does improve survival by some two to three months in some 50 per cent (of mesothelioma sufferers)," Prof Sansom said.

"But unfortunately, at the price that has been requested by the sponsor, it does not fall into the acceptable cost-effectiveness criteria." The PBAC last month again decided not to list